The market's romance with BioNTech has been building for weeks, fueled by a leadership handover, a sympathetic rally from ...

The timing could hardly be more awkward. Just as Lufthansa rolls out free Starlink satellite Wi-Fi on its first commercial ...

The disconnect between Rocket Lab's operational momentum and its share price has rarely been starker. While the company ...

Ethereum's recent recovery has exposed a striking disconnect beneath the surface. While retail investors holding between 100 ...

There's a familiar rhythm to turnaround stories: the operational metrics improve, management raises guidance, and yet the ...

The tank gearbox specialist Renk Group finds itself at an unusual crossroads. Its order books are bulging, analysts are ...

The pharma division of Bayer has quietly become the company's most reliable source of good news. The latest development ...

XPeng's Q2 earnings miss and 264,842-vehicle recall overshadow strong revenue growth, while weak Q3 guidance and robotics ...

Nvidia faces a pivotal earnings report amid a $6B licensing deal, Taiwan export indictment, and expected revenue of $92.2B—options imply a $280B market value swing.

The quiet resolution of a cross-border arbitration dispute has removed a lingering overhang from Sellas Life Sciences, even as the biotech's share price continu ...

The institutional buying spree coincides with a period of concrete operational milestones. IREN completed its acquisition of software provider Mirantis in early August, a move designed to bring cloud ...

The noise around XRP has rarely been louder, yet the most consequential developments for the Ripple ecosystem in recent days have had little to do with the toke ...